A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the findings of increased lactic acid and abnormal fat
distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or
Combivir (a pill containing lamivudine plus zidovudine) in HIV-positive patients taking
anti-HIV therapy including stavudine (d4T).
Phase:
Phase 4
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Abacavir Lamivudine Lamivudine, zidovudine drug combination Zidovudine